TherapeuticsMD Announces Full Year 2023 Financial Results [Yahoo! Finance]
TherapeuticsMD, Inc. (TXMD)
NASDAQ:AMEX Investor Relations:
ir.therapeuticsmd.com
Company Research
Source: Yahoo! Finance
the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. "We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, compared to net income from continuing operations of $1.1 million, or $0.12 per basic and $0.11 per diluted common share, for 2022. License and Service Revenues from Continuing Operations Gross license royalties totaled approximately $4.5 million under the Mayne License Agreement for the full year ending December 31, 2023. Included in this amount are $3.0 million of gross minimum royalty payments paid under the Mayne License Agreement. The Company recogn
Show less
Read more
Impact Snapshot
Event Time:
TXMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXMD alerts
High impacting TherapeuticsMD, Inc. news events
Weekly update
A roundup of the hottest topics
TXMD
News
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TherapeuticsMD, Inc. (NASDAQ: TXMD) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
TXMD
Sec Filings
- 4/29/24 - Form 10-K/A
- 3/29/24 - Form 10-K
- 3/29/24 - Form 8-K
- TXMD's page on the SEC website